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Analysis of A Novel Nonsense Mutation of Androgen Receptor Gene in Castration-Resistant 
Prostate Cancer  
 
Dong Han, PhD1, Kevin Valencia1, Shuai Gao, PhD1, and Changmeng Cai, PhD1 
1Center for Personalized Cancer Therapy, University of Massachusetts Boston 
 
BACKGROUND: Prostate cancer (PCa) is the second leading cause of cancer mortality in American 
men. The standard treatment for PCa is androgen deprivation therapy (ADT) that blocks transcriptional 
activity of androgen receptor, but ADT invariably leads to the development of castration-resistant form of 
PCa (CRPC) with restored activity of AR. CRPC can be further treated with more intensive ADTs, 
including CYP17-inhibitors to block intratumoral androgen synthesis and more potent AR antagonist 
(enzalutamide). Most CRPC patients still relapse after a year of treatment and AR activity appears to be 
restored again. By analyzing the tumor mRNA from a CRPC patient biopsy who had developed resistance 
to CYP17-inhibitor treatment, we identified a novel nonsense AR mutation on ligand binding domain 
(Q784sc), which presumably produces a C-terminal truncated form of AR protein that lacks ligand 
binding domain (LBD) and may mimic certain AR splice variants that also lack LBD. We thus 
hypothesized that AR-Q784sc mutant may gain the androgen-independent activity or may enhance the 
transcriptional activity of full-length AR under low androgen environment through dimerization with full-
length AR. 
 
METHOD: We utilized luciferase reporter assays to assess the activity of AR-Q784sc in absence or 
presence of androgens, and with/out full-length AR. We also examined the protein stability and cellular 
localization of AR-Q784sc using immunoblotting and immunofluorescence. Moreover, stable cell lines 
that overexpress AR and/or AR-Q784sc were generated to assess the transcription activity on endogenous 
target genes and on PCa cell growth.   
 
CONCLUSION: AR-Q784sc mutant produces a LBD truncated AR protein that does not have any 
transcriptional activity by it alone. However, AR-Q784sc can significantly enhance transcriptional 
activity of full-length AR though dimerization, indicating that the more intensive ADTs may allow CRPC 
cells to select for LBD truncated form of AR to further enhance the full-length AR activity under low 
androgen environment.  
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